Showing results (491-500 of 725) with videos related to
Sort By:
Pageof 73
Science (New York, N.Y.)|June 29, 1973
Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive ratsH Gavras, H B Brunner, E D Vaughan, et al.Hypertension (Dallas, Tex. : 1979)|February 1, 1992
Inhibition of nitric oxide, bradykinin, and prostaglandins in normal ratsY X Wang, I Gavras, T Wierzba, et al.Polish Journal of Pharmacology and Pharmacy|March 1, 1992
Synthesis and some pharmacological properties of new V1/V2 antagonists of arginine-vasopressin with structural changes at their N-terminalsB Lammek, E Konieczna, T Wierzba, et al.The New England Journal of Medicine|October 25, 1984
Renal revascularization in the azotemic hypertensive patient resistant to therapyC Y Ying, C P Tifft, H Gavras, et al.The Journal of Pharmacy and Pharmacology|January 1, 1991
Two highly effective V1/V2 antagonists of vasopressin containing novel thioacids at position 1B Lammek, Y X Wang, R Franco, et al.The Western Journal of Medicine|March 1, 1993
Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension. Do we need more clinical trials?M P Sambhi, H Gavras, J I Robertson, et al.Biochimica Et Biophysica Acta|March 4, 2000
A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out miceZ Zhao, K Makaritsis, C E Francis, et al.Hypertension (Dallas, Tex. : 1979)|December 1, 1996
Models of experimental hypertension in miceC Johns, I Gavras, D E Handy, et al.Journal of Clinical Pharmacology|March 1, 1997
Relationship between the prescriber's instructions and compliance with antibiotherapy in outpatients treated for an acute infectious diseaseO Favre, E Delacrétaz, M Badan, et al.Clinical Pharmacokinetics|January 1, 1997
Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonistsC Csajka, T Buclin, H R Brunner, et al.Pageof 73